Tag:
Prostate Cancer
Latest Headlines
Latest Headlines
J&J's Zytiga may be useful in early prostate cancer, too
A new study suggests Zytiga may be effective in early-stage disease. The small trial--it involved only 58 patients with localized, high-risk cancer--found that Zytiga wiped out or nearly wiped out tumors in one-third of them.
New discount persuades NICE to bless J&J's Zytiga
Britain's cost-effectiveness watchdog reversed its decision against the Johnson & Johnson prostate cancer pill, thanks to the company's new discount offer.
FDA withdraws hold on GTx's prostate cancer drug
The FDA lifted a clinical hold on the experimental cancer drug Capesaris after reviewing the company's response and plans for a Phase II study involving patients with castration-resistant prostate cancer.
Amgen gets a no from the FDA on extended use of Xgeva
The FDA told Amgen no to an expanded use of its cancer treatment Xgeva, one of the company's most important drugs, saying the company could try again with more data.
Oregano attacks prostate cancer cells in lab experiment
Scientists report that a chemical in oregano, carvacrol, effectively killed off prostate cancer cells in a lab experiment.
Sanofi colorectal cancer contender Zaltrap suffers a PhIII trial setback
Sanofi and Regeneron's opened their update on the cancer drug Zaltrap (aflibercept) on a sweet note: The FDA has granted a priority review of their NDA for colorectal cancer.
High-profile investigator tapped to lead $10M prostate cancer program
Charles Sawyers has been tapped to help lead a $10 million effort to test personalized treatments for prostate cancer.
Tokai unveils promising Phase I data for 'triple whammy' prostate cancer contender
Cambridge, MA-based Tokai Pharmaceuticals presented a promising set of Phase I data pointing to the early efficacy of its "triple whammy" pill for castration-resistant prostate cancer.
Provenge critic gaining attention after taking shots at study data
Dendreon's pioneering cancer vaccine, Provenge, is under fire again.
New Zytiga use could double sales potential
Analysts are rejigging their sales estimates for Johnson & Johnson's prostate cancer pill Zytiga , on the promise that it could target a much larger set of patients.
